Literature DB >> 20686957

Hypoxic tumors and their effect on immune cells and cancer therapy.

Patricia Yotnda1, Danli Wu, Anna May Swanson.   

Abstract

The abnormal decrease or the lack of oxygen supply to cells and tissues is called hypoxia. This condition is commonly seen in various diseases such as rheumatoid arthritis and atherosclerosis, also in solid cancers. Pre-clinical and clinical studies have shown that hypoxic cancers are extremely aggressive, resistant to standard therapies (chemotherapy and radiotherapy), and thus very difficult to eradicate. Hypoxia affects both the tumor and the immune cells via various pathways. This review summarizes the most common effects of hypoxia on immune cells that play a key role in the anti-tumor response, the limitation of current therapies, and the potential solutions that were developed for hypoxic malignancies.

Entities:  

Mesh:

Year:  2010        PMID: 20686957     DOI: 10.1007/978-1-60761-786-0_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  18 in total

1.  Clusterin and chemotherapy sensitivity under normoxic and graded hypoxic conditions in colorectal cancer.

Authors:  David Kevans; Sheeona Gorman; Miriam Tosetto; Kieran Sheahan; Diarmuid O'Donoghue; Hugh Mulcahy; Jacintha O'Sullivan
Journal:  J Gastrointest Cancer       Date:  2012-06

Review 2.  The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.

Authors:  Larry H Matherly; Zhanjun Hou; Aleem Gangjee
Journal:  Cancer Chemother Pharmacol       Date:  2017-11-10       Impact factor: 3.333

Review 3.  Targeting hypoxia in cancer therapy.

Authors:  William R Wilson; Michael P Hay
Journal:  Nat Rev Cancer       Date:  2011-06       Impact factor: 60.716

4.  Disruption of kv1.3 channel forward vesicular trafficking by hypoxia in human T lymphocytes.

Authors:  Ameet A Chimote; Zerrin Kuras; Laura Conforti
Journal:  J Biol Chem       Date:  2011-11-30       Impact factor: 5.157

Review 5.  Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.

Authors:  Annamaria Rapisarda; Giovanni Melillo
Journal:  Nat Rev Clin Oncol       Date:  2012-04-24       Impact factor: 66.675

6.  Rational drug repositioning guided by an integrated pharmacological network of protein, disease and drug.

Authors:  Hee Sook Lee; Taejeong Bae; Ji-Hyun Lee; Dae Gyu Kim; Young Sun Oh; Yeongjun Jang; Ji-Tea Kim; Jong-Jun Lee; Alessio Innocenti; Claudiu T Supuran; Luonan Chen; Kyoohyoung Rho; Sunghoon Kim
Journal:  BMC Syst Biol       Date:  2012-07-02

7.  Emerging evidence of the physiological role of hypoxia in mammary development and lactation.

Authors:  Yong Shao; Feng-Qi Zhao
Journal:  J Anim Sci Biotechnol       Date:  2014-01-21

8.  Hypoxia-Responsive, Polymeric Nanocarriers for Targeted Drug Delivery to Estrogen Receptor-Positive Breast Cancer Cell Spheroids.

Authors:  Babak Mamnoon; Li Feng; Jamie Froberg; Yongki Choi; Venkatachalem Sathish; Sanku Mallik
Journal:  Mol Pharm       Date:  2020-09-29       Impact factor: 5.364

9.  The Influence of Hypoxia and pH on Bioluminescence Imaging of Luciferase-Transfected Tumor Cells and Xenografts.

Authors:  Ashraf A Khalil; Mark J Jameson; William C Broaddus; Peck Sun Lin; Seth M Dever; Sarah E Golding; Elizabeth Rosenberg; Kristoffer Valerie; Theodore D Chung
Journal:  Int J Mol Imaging       Date:  2013-07-07

10.  Hypoxia regulates stemness of breast cancer MDA-MB-231 cells.

Authors:  Jing Xie; Yong Xiao; Xiao-yan Zhu; Zhou-yu Ning; Hai-fan Xu; Hui-min Wu
Journal:  Med Oncol       Date:  2016-04-01       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.